American Century Companies Inc. increased its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 2.5% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 197,527 shares of the medical instruments supplier’s stock after purchasing an additional 4,795 shares during the period. American Century Companies Inc. owned 1.05% of LeMaitre Vascular worth $6,167,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Russell Investments Group Ltd. boosted its stake in shares of LeMaitre Vascular by 5.6% during the second quarter. Russell Investments Group Ltd. now owns 158,761 shares of the medical instruments supplier’s stock valued at $4,956,000 after purchasing an additional 8,348 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in shares of LeMaitre Vascular by 52.3% during the first quarter. Ameriprise Financial Inc. now owns 201,508 shares of the medical instruments supplier’s stock valued at $4,963,000 after purchasing an additional 69,186 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of LeMaitre Vascular by 1.6% during the first quarter. Bank of New York Mellon Corp now owns 88,552 shares of the medical instruments supplier’s stock valued at $2,181,000 after purchasing an additional 1,408 shares in the last quarter. Thomson Horstmann & Bryant Inc. boosted its stake in shares of LeMaitre Vascular by 1.8% during the second quarter. Thomson Horstmann & Bryant Inc. now owns 365,977 shares of the medical instruments supplier’s stock valued at $11,425,000 after purchasing an additional 6,638 shares in the last quarter. Finally, MARSHALL WACE ASIA Ltd bought a new position in shares of LeMaitre Vascular during the first quarter valued at approximately $988,000. Hedge funds and other institutional investors own 66.32% of the company’s stock.

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 11,300 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $32.79, for a total transaction of $370,527.00. Following the completion of the transaction, the chief executive officer now owns 3,405,508 shares in the company, valued at approximately $111,666,607.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO George W. Lemaitre sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $37.13, for a total transaction of $556,950.00. Following the transaction, the chief executive officer now owns 3,325,508 shares of the company’s stock, valued at approximately $123,476,112.04. The disclosure for this sale can be found here. Insiders have sold a total of 373,121 shares of company stock valued at $12,825,992 in the last quarter. 23.70% of the stock is currently owned by company insiders.

LMAT has been the subject of a number of analyst reports. Canaccord Genuity cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating and set a $28.00 target price for the company. in a research report on Monday, July 10th. Benchmark Co. cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Monday, July 10th. They noted that the move was a valuation call. Craig Hallum initiated coverage on shares of LeMaitre Vascular in a research report on Tuesday, June 6th. They set a “hold” rating and a $31.00 target price for the company. BidaskClub cut shares of LeMaitre Vascular from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Finally, Zacks Investment Research cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Tuesday, July 4th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $30.17.

TRADEMARK VIOLATION NOTICE: “American Century Companies Inc. Acquires 4,795 Shares of LeMaitre Vascular, Inc. (LMAT)” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/09/09/american-century-companies-inc-acquires-4795-shares-of-lemaitre-vascular-inc-lmat.html.

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) opened at 37.60 on Friday. LeMaitre Vascular, Inc. has a 52-week low of $17.70 and a 52-week high of $37.90. The stock has a market cap of $715.23 million, a PE ratio of 53.71 and a beta of 0.67. The company’s 50-day moving average is $33.99 and its 200-day moving average is $29.05.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $0.23 EPS for the quarter, topping the consensus estimate of $0.17 by $0.06. LeMaitre Vascular had a net margin of 14.19% and a return on equity of 15.02%. The company had revenue of $25.80 million during the quarter, compared to analysts’ expectations of $25.42 million. During the same quarter in the previous year, the business posted $0.14 EPS. The firm’s revenue was up 15.2% on a year-over-year basis. Equities analysts anticipate that LeMaitre Vascular, Inc. will post $0.80 EPS for the current year.

LeMaitre Vascular declared that its board has approved a stock repurchase program on Thursday, July 27th that permits the company to buyback $7.50 million in shares. This buyback authorization permits the medical instruments supplier to reacquire up to 1.4% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s leadership believes its stock is undervalued.

The company also recently declared a quarterly dividend, which was paid on Thursday, September 7th. Shareholders of record on Wednesday, August 23rd were issued a dividend of $0.055 per share. This represents a $0.22 annualized dividend and a yield of 0.59%. The ex-dividend date of this dividend was Monday, August 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 31.88%.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Stock Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related stocks with our FREE daily email newsletter.